# A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy

> **NCT00587067** · PHASE2 · COMPLETED · sponsor: **Memorial Sloan Kettering Cancer Center** · enrollment: 34 (actual)

## Conditions studied

- Hepatic Cancer

## Interventions

- **DRUG:** FLOXURIDINE

## Key facts

- **NCT ID:** NCT00587067
- **Lead sponsor:** Memorial Sloan Kettering Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2016-05-19
- **Final completion:** 2016-05-19
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2023-04-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00587067

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00587067, "A Phase II Study of Continuous Hepatic Arterial Infusion With Floxuridine (FUDR) and Dexamethasone (DEX) in Patients With Unresectable Primary Hepatic Malignancy". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00587067. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*